Fondaparinux reducerede incidensen af død/ re- MI efter 30 dage signifikant, fra 11, 1% i kontrolgruppen til 9, 7% i fondaparinuxgruppen (hazard rate 0, 86; 95% CI 0, 77- 0, 96; p = 0, 008).
The incidence of death/ re-MI at Day 30 was significantly reduced from 11.1% for the control group to 9.7% for the fondaparinux group (hazard ratio 0.86, 95% CI, 0.77, 0.96, p = 0.008).